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Conclusions These results show that NYHA score and 6 minutes’ walk
test are useful to discriminate functional status in obese patients compared to
others but unsatisfying because can surestimates severity of obese heart failure
patients, the VO2 max is more useful.
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Background heart failure with reduced ejection fraction (HF-REF) is asso-
ciated with left ventricular remodeling in most patients which is grossly
defined by LV dilation, and is associated with poor prognosis. Positive or
reverse remodeling (RR) was also described but its exact contribution is
poorly documented. 
Aim to analyze prevalence of RR in a cohort of outpatients with HF-REF
and to characterize its determinants and prognostic impact.
Methods inclusion criteria were: available detailed echographic files; beta-
blockers ACE-I or ARB introduced before the study; left ventricular EF (LVEF)
<0.45 and left ventricular end diastolic dimension >33mm/m2 at the first echog-
raphy; at least one other examination between 3 and 12 months; clinical follow-
up of 3 years or more (cardiac death or cardiac transplantation). RR was defined
as the combination of a decrease of LV end diastolic diameter >10% and an
increase in LVEF >10% (or last EF >0.50) between the two echocardiographies.
Results we included 196 patients between 2008 and 2010. RR was
observed in 21 patients (10%). As compared with others patients, RR was
associated with significantly higher BMI (27.3 vs 25.3), obesity (28 vs 10%),
de novo HF (81 vs 46%) and lower initial LVEF (0.26 vs 0.30). In multivar-
iate regression analysis, de novo HF and obesity were independently predic-
tive of the RR. Over amean follow-up of 60 months, the rate of death or
cardiac transplantation was 4% in RR patients and 14% in the other group
(p<0.01). In Cox-regression analysis, independent predictors of prognosis
were de novo HF, obesity and RR (p<0.01). After adjustement, RR remains
associated with better prognosis (HR 0.22; CI95% 0.06-0.95; p=0.04).
Conclusion RR occurs in a small proportion of patients with HF-REF and
is related to good prognosis. While de novo HF appears to be the strongest
determinant of RR, our results suggest that obesity could be a novel and
intriguing player in underlying mechanisms of RR. 
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Objective to evaluate variations in sexual and erectile function in subjects
with chronic heart failure (CHF) after optimization of CHF treatment.
Methods 160 patients men (age range 40-76 years; mean age 60 years),
with CHF and erectile dysfunction (ED), were divided two groups, one under
syptomatic treatment of ED; were asked all of them to complete the Interna-
tional Index of Erectile Function IIEF-5 before (at baseline) and 3 months
after optimization of treatment of CHF.
Results Among 160 patients studied, 47.3% have an optimal treatment of
CHF versus 52,7% have not, more than 60% of patients with optimal treat-
ment of CHF (and without symptomatic treatment of ED) showed significant
improvements on the 5 domains of the IIEF-5, compared to 25% of patients
without optimal treatment and under symptomatic treatment of ED (the differ-
ence was statistically significant).
Conclusion the results of this study support that optimal treatment of CHF
improves erectile function in patient with erectile dysfunction secondary to
CHF better than symptomatic treatment alone.
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Background Hemoglobin SC (HbSC) disease and homozygous sickle-cell
anemia (SCA) are the most frequent genotypes (accounting for respectively
25% and 70%) of sickle-cell disease. Although the SCA cardiac involvement
was well studied, the cardiac remodeling associated to HbSC has never been
specifically investigated. The aim of the study was to describe the HbSC car-
diac remodeling versus SCA.
Method Using a case-control design, 61 HbSC (mean age 31.3±10.0 years,
36 women) patients underwent a comprehensive echocardiography and were
compared to 61 SCA patients in stable conditions. LV end diastolic volume
index and LV ejection fraction were measured by Simpson method. LV mass
index, left atrial volume index, septal E/e’ ratio, peak tricuspid regurgitation
velocity (TRV) and cardiac index were also measured as recommended. All
the parameters were the average of three measures.
Results Both LV morphological and diastolic functional parameters dif-
fered dramatically between the two groups of patients (table, mean±SD).
Moreover, the pulmonary artery systolic pressure as estimated by TRV was
lower in HbSC patients. 
Conclusions Cardiac remodeling is very different in HbSC compared to
SCA. Clinical interpretation of echocardiography data should be adjusted to
each variant of the disease. Moreover, this study is further evidence that the
both genotypes of sickle-cell disease have different organ involvements and
should not be pooled in clinical studies. Specific guidelines for follow up of
HbSC patients should be established.
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Background The risk of myocardial pathology increases several times
when type 2 diabetes mellitus (T2DM) is combined with other metabolic dis-
Abstratct 0147 – Table 
SCA patients 
(n=61) 
HbSC patients 
(n=61) 
p value
Heart rate (beats/min) 70±11 72±10 0.26
LV mass index (g/m²) 103±26 77±16 <0.0001
LV end diastolic volume index 
(ml/m²) 92±19 64±15 <0.0001
Cardiac index (L/min/m²) 4.2±1.0 3.1±0.6 <0.0001
LV ejection fraction (%) 60±5 61±6 0.88
Septal E/e’ ratio 10.9±2.4 7.2±2.1 <0.0001
Left atrial volume index 
(ml/m²) 51.1±11.9 33.8±7.5 <0.0001
Tricuspid regurgitation 
velocity (m/s) 2.57±0.26 2.26±0.23 <0.0001
Tricuspid regurgitation 
velocity >2.5m/s, n(%) 34 (56) 4 (7) <0.0001
